Public markets are now ready to price hardware-enabled subscription businesses at premium multiples again.

The transition from a pure-play hardware vendor to a high-margin health data platform has allowed Oura to achieve a $11 billion valuation. By securing recurring revenue through a subscription model, they have decoupled growth from cyclical hardware refresh cycles.

What Happened

Oura Health Oy has confidentially filed for an IPO in the United States, signaling the culmination of a rapid scaling phase that saw sales double between 2024 and 2025. The company has moved 5.5 million units and projects 2026 revenue to exceed $1.5 billion. Their model combines high-ASP hardware with a mandatory $5.99 monthly subscription fee, which currently drives roughly 20% of their total top line.

Why It Matters

First-order: This sets a new benchmark for exit valuations in the health-tech sector, creating a liquidity event for long-term backers like Fidelity and ICONIQ. It validates the ‘ring’ form factor as a legitimate competitor to the wrist-worn ecosystem, proving that consumer adoption is no longer limited to major smartphone OEMs.

Second-order: Expect a wave of capital to flow toward B2B and enterprise wellness applications that integrate with Oura’s API. As they pivot to ‘Oura for Business,’ they are building a defensive moat against enterprise-focused health platforms, forcing competitors to prioritize data integration or risk obsolescence.

Third-order: The broader wearables industry will face increased pressure to prove retention-based revenue. Investors will scrutinize the ‘hardware-as-a-service’ metrics of Oura’s peers, potentially compressing valuations for companies that remain strictly transactional or hardware-only.

The Numbers

  • $11B valuation as of October 2025 (Source: Internal/Market Data)
  • 5.5 million units sold to date (Source: TechCrunch)
  • $1.5B projected 2026 revenue (Source: Internal/Market Data)
  • 20% of revenue derived from subscriptions (Source: Internal/Market Data)

What To Watch

  • Margin Expansion: Watch the Q3/Q4 earnings calls for shifts in the hardware/subscription revenue split.
  • IP Enforcement: Monitor how Oura manages remaining competitive patent disputes with RingConn and Ultrahuman post-listing.
  • Enterprise Adoption: Look for major institutional health insurance partnerships that leverage ‘Oura for Business’ as a clinical tool.